EGFR and adenocarcinoma: KRAS mutation is present in about 30% of adenocarcinoma 43, 44 which makes A549 lung cancer model good for our experiments because we would be directly targeting EGFR family and as the peptidomimetic would be inhibiting the proliferation of A549, which means KRAS is also indirectly affected that comprises 30% of adenocarcinoma.